中华老年心脑血管病杂志

参考文献

[1]王陇德.全国居民营养与健康状况调查2002综合报告.北京:人民卫生出版社,2002.53-57.

[2]王薇,赵冬.中国老年人高血压的流行病学.中华老年医学杂志,2005,24:246-247.

[3]方向华,汤哲,平光宇,等.北京社区老年人群高血压防治现况的综合评价.中华老年医学杂志,2004,23:659-662.

[4]王薇,赵冬,刘静,等.中国35~64岁人群血压水平与10年心血管病发病危险的前瞻性研究.中华内科杂志,2004,43:730-734.

[5]Kwok L,Bernard MY,Cheung Y,et al.Prevalence,aware-ness,treat ment,and control of hypertension among United States adults1999-2004.Hypertension,2007,49:69-75.

[6]Franklin SS,Gustin W,Wong ND,et al.Hemodynamic pat-terns of age-related changes in blood pressure.The Framing-ham Heart Study.Circulation,1997,96:308-315.

[7]吴锡桂,段秀芳,黄广勇,等.我国老年人群单纯收缩期高血压患病率及影响因素.中华心血管病杂志,2003,31:456-459.

[8]Manfredini R,Boari B,Portaluppi F.Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives.Circulation,2003,108:e72-e73.

[9]中国高血压防治指南修订委员会.中国高血压防治指南(修订版).高血压杂志,2005,13.(Suppl):42-43.

[10]Japanese Society of Hypertension.Japanese Society of Hyper-tension guidelines for the management of hypertension(JSH2004).Hypertens Res,2006,29:S1-S105.

[11]Bobrie G,Chatellier G,Genes N,et al.Cardiovascular progno-sis of“masked hypertension”detected by blood pressure self-measurement in elderly treated hypertensive patients.JAMA,2004,291:1342-1349.

[12]Miyakawa M.Clinical significance of home blood pressure mo-nitoring and its application to daily clinical practice.Nippon Rinsho,2005,63:909-915.

[13]Okaishi K,Mori moto S,Matsumoto M.Guidelines for antihy-pertensive treat ment of elderly hypertensive patients without complications based on EBM.Nippon Rinsho,2005,63:1016-1027.

[14]Lloyd-Jones DM,Evans JC,Larson MG,et al.Cross-classifica-tion of JNC VI blood pressure stages and risk groups in the Framingham Heart Study.Arch Intern Med,1999,159:2206-2212.

[15]Mancia G,De Backer G,Dominiczak A,et al.2007Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC).Eur Heart J,2007,28:1462-1536.

[16]Iriarte M,Murga N,Morillas M,et al.Congestive heart failure fromleft ventricular diastolic dysfunction in systemic hyper-tension.AmJ Cardiol,1993,71:308-312.

[17]Zanchetti A,Cuspidi C,Comarella L,et al.Left ventricular di-astolic dysfunction in elderly hypertensives:results of the APROS-diadys study.J Hypertens,2007,25:2158-2167.

[18]Hennersdorf MG,Schueller PO,Steiner S,et al.Prevalence of paroxysmal atrial fibrillation depending on the regression of left ventricular hypertrophy in arterial hypertension.Hyper-tens Res,2007,30:535-540.

[19]Laurent S,Cockcroft J,Van Bortel L,et al.Expert consensus document on arterial stiffness:methodological issues and clin-ical applications.Eur Heart J,2006,27:2588-2605.

[20]Hasi mu B,Li J,Nakayama T,et al.Ankel brachial index as a marker of atherosclerosisin Chinese patients with high cardio-vascular risk.Hypertens Res,2006,29:23-28.

[21]Rastas S,Verkkoniemi A,Polvikoski T,et al.Atrial fibrilla-tion,stroke,and cognition A longitudinal population-based study of people aged85and older.Stroke,2007,38:1454-1460.

[22]Kario K,Shi mada K,Schwartz JE,et al.Silent and clinically o-vert strokein older Japanese subjects with white-coat and sus-tained hypertension.J Cardiol,2002,39:52-54.

[23]Vermeer SE,Koudstaal PJ,Oudkerk M,et al.Prevalence and risk factors of silent brain infarcts in the population-based RotterdamScan Study.Stroke,2002,33:21-25.

[24]Chobanian AV,Bakris GL,Black HR,et al.Heart,Lung,and Blood Institute;National High Blood Pressure Education Pro-gram Coordinating Committee.Seventh report of the Joint Na-tional Committee on Prevention,Detection,Education,and Treat ment of High Blood Pressure.Hypertension,2003,42:1206-1252.

[25]SHEP Collaborative Research Group.Prevention of stroke by antihypertensive drug treat ment in older persons withisolated systolic hypertension:final results of the Systolic Hyperten-sionin the Elderly Program(SHEP).JAMA,1991,265:3255-3264.

[26]Staessen JA,Fagard R,Thijs L,et al.For the Syst-EUR Col-laborative Group.Systolic hypertensionin comparison of pla-cebo and active treat ment for older patients withisolated sys-tolic hypertension.Lancet,1997,350:757-764.

[27]Liu LS,Wang JG,Gong LS,et al.Comparison of active treat-ment and placebo in older Chinese patients with isolated sys-tolic hypertension.J Hypertens,1998,16:1823-1829.

[28]Kannel WB,D′Agostino RB,Silbershatz H.Blood pressure and cardiovascular morbidity and mortality rates in elderly.Am Heart J,1997,134:758-763.

[29]Pepine CJ,Handberg EM,Cooper-Dehoff RM,et al.I NVEST Investigators.A calcium antagonist vs a non-calcium antago-nist hypertension treat ment strategy for patients with coro-nary artery disease.The International Verapamil-Trandolapril Study(I NVEST):a randomized controlledtrial.JAMA,2003,290:2805-2816.

[30]Insua JT,Sacks HG,Lau TS,et al.Drug treat ment of hyper-tensionin the elderly:a meta-analysis.Ann Intern Med,1994,121:355-362.

[31]The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in moderately hypercholesterolemic,hypertensive patients randomized to pravastatin vs usual care.The Antihypertensive and Lipid-Lowing Treat ment to Prevent Heart Attack Trial(ALLHAT-LLT).JAMA,2002,288:2998-3007.

[32]Brown MJ,Pal mer CR,Castaigne A,et al.Morbidity and mor-tality in patients randomized to double-blind treat ment with a long-acting calcium-channel blocker or diuretic in the interna-tional Nifedipine GITSstudy:Intervention as a Goal in Hyper-tension Treat ment(I NSIGHT).Lancet,2000,356:366-372.

[33]Julius S,Kjeldsen ES,Weber M,et al.The VALUE trial group outcomes in hypertensive patients at high cardiovascu-lar risk treated with regi mens based on valsartan of amlodip-ine:the VALUE randomized trial.Lancet,2004,363:2022-2031.

[34]Liu LS,Zhang YQ,Liu GZ,et al.For FEVER Study Group.The Felodipine Event Reduction(FEVER)study:A random-ized long-termplacebo controlled trial in Chinese hypertensive patients-design and principle results.J Hypertens,2005,23:s118.

[35]Hansson L,Lindhol m LH,Niskanen L,et al.Effect of angio-tensin-converting-enzyme inhibition compared with conven-tional therapy on cardiovascular morbidity and mortality in hypertension:the Captopril Prevention Project(CAPPP)ran-domized trial.Lancet,1999,353:611-616.

[36]Wing LMH,Reid CM,Ryan P,et al.A comparison of out-comes with angiotensin coverting enzyme inhibitors and diu-retics in the elderly(the Second Australian National Blood Pressure Study).N Engl J Med,2003,348:583-592.

[37]Kjeldsen SE,Dahlof B,Devereux RB,et al.Effects of Iosartan on cardiovascular morbidity and mortalityin patients withiso-lated systolic hypertension and left ventricular hypertension:aLosartan intervention for Endpoint reduction(LIFE)sub-study.JAMA,2002,288:1491-1498.

[38]Lithell H,Hansson L,Skogg L,et al.For the SCOPE Study Group.The Study on Cognition and Prognosis in the Elderly(SCOPE).Principal results of a randomized double-blind in-tervention trial.J Hypertens,2003,21:875-886.

[39]Lindhol m LH,Carberg B,Samuelsson O.Should beta blockers remain first choice in the treat ment of pri mary hypertension?A meta-analysis.Lancet,2005,366:1545-1553.

[40]Marfella R,Siniscalchi M,Portoghese M,et al.Morning blood pressure surge as a destabilizing factor of atherosclerotic plaque:role of ubiquitin-proteasome activity.Hypertension,2007,49:784-791.

[41]Eguchi K,Kario K,Shi mada K.Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension.Am J Cardiol,2003,92:621-624.

[42]Gosse P,Neutel J M,Schumacher H,et al.The effect of tel m-isartan and ramipril on early morning blood pressure surge:a pooled analysis of two randomized clinical trials.Blood Pres-sure Monitoring,2007,12:141-147.

[43]Patel PV,Wong JL,Arora R.The morning blood pressure surge:therapeutic i mplications.Journal of Clinical Hyperten-sion,2008,10:140-145.

[44]Zampaglione B,Pascale P,Marchisio M,et al.Hypertensive urgencies and emergencies:prevalence and clinical presenta-tion.Hypertension,1996,27:144-147.

[45]Vaughan C,Dealnty N.Hypertensive emergencies.Lancet,2000,356:411-417.

[46]中华人民共和国卫生部疾病控制司中华医学会神经病学分会.中国脑血管病防治指南.北京:人民卫生出版社,2007.61-62.

[47]Gandhi SK,Powers JC,Nomeir AM,et al.The pathogenesis of acute pul monary edema associated with hypertension.N Engl J Med2001,344:17-22.

[48]中华人民共和国卫生部疾病控制司中华医学会糖尿病学分会.中国糖尿病防治指南.北京:北京大学医学出版社,2004.33-34.

[49]血管紧张素转换酶抑制剂在心血管病中应用中国专家共识.中华心血管病杂志,2007,35:97-106.

[50]Ankel F.Aortic dissection.Marx J.editors.Rosens emergency medicine.5th ed.St.Louis,Mo:Mosby,2003.1171-1176.

[51]Healey JS,Baranchuk A,Crystal E,et al.Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers:a meta-analysis.J Am Coll Car-diol,2005,45:1832-1839.

[52]ACC/AHA/ESC2006Guidelines for the Management of Pa-tients with Atrial Fibrillation.Circulation,2006,114:700-752.